1 – 20 of 22
- show: 20
- |
- sort: year (new to old)
Close
Embed this list
<iframe src=" "
width=" "
height=" "
allowtransparency="true"
frameborder="0">
</iframe>
- 2023
-
Mark
Transcriptomic subtyping of malignant peripheral nerve sheath tumours highlights immune signatures, genomic profiles, patient survival and therapeutic targets
(
- Contribution to journal › Article
- 2021
-
Mark
Outcome in dedifferentiated chondrosarcoma for patients treated with multimodal therapy : Results from the EUROpean Bone Over 40 Sarcoma Study
(
- Contribution to journal › Article
- 2018
-
Mark
Adjuvant chemotherapy and postoperative radiotherapy in high-risk soft tissue sarcoma patients defined by biological risk factors—A Scandinavian Sarcoma Group study (SSG XX)
(
- Contribution to journal › Article
-
Mark
Inferior survival for patients with malignant peripheral nerve sheath tumors defined by aberrant TP53
(
- Contribution to journal › Article
-
Mark
EURO-B.O.S.S. : A European study on chemotherapy in bone-sarcoma patients aged over 40: Outcome in primary high-grade osteosarcoma
(
- Contribution to journal › Article
- 2017
-
Mark
The Scandinavian Sarcoma Group Central Register : 6,000 patients after 25 years of monitoring of referral and treatment of extremity and trunk wall soft-tissue sarcoma
(
- Contribution to journal › Article
- 2015
-
Mark
Referral patterns, treatment and outcome of high-grade malignant bone sarcoma in Scandinavia-SSG Central Register 25 years' experience.
(
- Contribution to journal › Article
-
Mark
Methylated RASSF1A in malignant peripheral nerve sheath tumors identifies neurofibromatosis type 1 patients with inferior prognosis.
(
- Contribution to journal › Article
- 2014
-
Mark
Bone sarcomas : ESMO clinical practice guidelines for diagnosis, treatment and follow-up
(
- Contribution to journal › Article
- 2011
-
Mark
Results of the Scandinavian Sarcoma Group XIV protocol for classical osteosarcoma 63 patients with a minimum follow-up of 4 years
(
- Contribution to journal › Article
- 2010
-
Mark
Genomic Changes in Chromosomes 10, 16, and X in Malignant Peripheral Nerve Sheath Tumors Identify a High-Risk Patient Group.
(
- Contribution to journal › Article
- 2009
-
Mark
t(19;22)(q13;q12) Translocation Leading to the Novel Fusion Gene EWSRI-ZNF444 in Soft Tissue Myoepithelial Carcinoma
(
- Contribution to journal › Article
-
Mark
SSG pathology review experiences and histological grading of malignancy in sarcomas
(
- Contribution to journal › Scientific review
-
Mark
Cytogenetic Analysis of 101 Giant Cell Tumors of Bone: Nonrandom Patterns of Telomeric Associations and Other Structural Aberrations
(
- Contribution to journal › Article
-
Mark
Scandinavian experience in classical osteosarcoma Results of the SSG XIV protocol
(
- Contribution to journal › Article
-
Mark
Identification of p53 as a strong predictor of survival for patients with malignant peripheral nerve sheath tumors
(
- Contribution to journal › Article
- 2008
-
Mark
Detection of a t(1;22)(q23;q 12) translocation leading to an EWSR1-PBX1 fusion gene in a myoepithelioma
(
- Contribution to journal › Article
- 2007
-
Mark
Clinical course of nonvisceral soft tissue leiomyosarcoma in 225 patients from the Scandinavian Sarcoma Group
(
- Contribution to journal › Article
-
Mark
Diagnostic and prognostic gene expression signatures in 177 soft tissue sarcomas: hypoxia-induced transcription profile signifies metastatic potential.
(
- Contribution to journal › Article
- 2006
-
Mark
Deregulation of HMGA2 in an aggressive angiomyxoma with t(11;12)(q23;q15)
(
- Contribution to journal › Article